Figure 3
Figure 3. Phase 2 mobilization data. (A) Change in AML blasts in the peripheral blood expressed as fold-change relative to baseline at 6 hours (n = 37) and 24 hours (n = 31) after administration of plerixafor 0.24 mg/kg. (B) Correlation between CXCR4 expression (CD184 12G5) in the peripheral blood at baseline and AML blast mobilization at 6 hours.

Phase 2mobilization data. (A) Change in AML blasts in the peripheral blood expressed as fold-change relative to baseline at 6 hours (n = 37) and 24 hours (n = 31) after administration of plerixafor 0.24 mg/kg. (B) Correlation between CXCR4 expression (CD184 12G5) in the peripheral blood at baseline and AML blast mobilization at 6 hours.

Close Modal
This Feature Is Available To Subscribers Only

or Create an Account

Close Modal
Close Modal